Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group

Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate...

Full description

Bibliographic Details
Main Authors: Candice Hober, Lisa Fredeau, Anne Pham-Ledard, Marouane Boubaya, Florian Herms, Philippe Celerier, François Aubin, Nathalie Beneton, Monica Dinulescu, Arnaud Jannic, Nicolas Meyer, Anne-Bénédicte Duval-Modeste, Laure Cesaire, Ève-Marie Neidhardt, Élodie Archier, Brigitte Dréno, Candice Lesage, Clémence Berthin, Nora Kramkimel, Florent Grange, Julie de Quatrebarbes, Pierre-Emmanuel Stoebner, Nicolas Poulalhon, Jean-Philippe Arnault, Safia Abed, Bertille Bonniaud, Sophie Darras, Valentine Heidelberger, Suzanne Devaux, Marie Moncourier, Laurent Misery, Sandrine Mansard, Maxime Etienne, Florence Brunet-Possenti, Caroline Jacobzone, Romain Lesbazeilles, François Skowron, Julia Sanchez, Stéphanie Catala, Mahtab Samimi, Youssef Tazi, Dominique Spaeth, Caroline Gaudy-Marqueste, Olivier Collard, Raoul Triller, Marc Pracht, Marc Dumas, Lucie Peuvrel, Pierre Combe, Olivier Lauche, Pierre Guillet, Yves Reguerre, Ingrid Kupfer-Bessaguet, David Solub, Amélie Schoeffler, Christophe Bedane, Gaëlle Quéreux, Sophie Dalac, Laurent Mortier, Ève Maubec
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
PD-1–blocking antibody
cemiplimab
cutaneous squamous cell carcinoma
real-life setting
immunocompromised
chronic dermatosis
Online Access:https://www.mdpi.com/2072-6694/13/14/3547

Internet

https://www.mdpi.com/2072-6694/13/14/3547

Similar Items